Furthermore, due to subsequent sustained Akt- and MAPK-pathway activation, hVps37A-deficient cells become irresponsive to inhibition by the therapeutic antibody cetuximab....hVps37A expression might be exploitable as a prognostic and predictive marker in ovarian cancer and possibly in other cancer entities as well....